Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 15, 2017
Clinical News

Opdivo plus Yervoy gets Priority Review for RCC

BioCentury | Dec 8, 2017
Clinical News

EC approves Opdivo plus Yervoy combo for RCC

BioCentury | Sep 8, 2017
Clinical News

FDA approves BMS's Yervoy in pediatric melanoma

BioCentury | Jan 20, 2017
Clinical News

Yervoy regulatory update

BioCentury | Oct 17, 2016
Clinical News

Yervoy ipilimumab: Phase III data

BioCentury | Oct 17, 2016
Clinical News

Yervoy ipilimumab: Phase III data

BioCentury | Jun 6, 2016
Clinical News

Yervoy ipilimumab: Interim Phase II data

BioCentury | Nov 9, 2015
Clinical News

Yervoy ipilimumab regulatory update

BioCentury | Nov 2, 2015
Clinical News

Yervoy ipilimumab: Phase III discontinued

Items per page:
1 - 10 of 50